News

During ‘World Antimicrobial Awareness Week’ Mast unite to preserve antimicrobials by continuing to support Antibiotic stewardship, in providing and continually updating its range of in vitro diagnostic (IVD) Antimicrobial Resistance (AMR) products to reduce time to appropriate treatment decision and allow for a more targeted use of therapy against infection.

MAST^®ALEX-MRSA (RST501); for the detection of penicillin binding protein 2’ (PBP2’) and confirmation of Methicillin resistant Staphylococcus aureus (MRSA)

COVID-19 Update

Mast is pleased to announce the launch of NEW additions to the MASTDISCS^® AST range for EUCAST and CLSI methodology:

Mast Group Ltd. are pleased to announce the expansion of their molecular product portfolio with the launch of the New MAST ISOPLEX^® CRE-ART  kit for the rapid molecular detection of carbapenemase producing organisms (CPOs).

Mast are pleased to announce the launch of the NEW  MASTDISCS^® Combi  ESBL Detection Set (EUCAST) with the new disc potencies as recommended by EUCAST for the reliable detection of ESBL producing Enterobacterales.

MAST^® ASSURE Bacterial Agglutinating Antisera products are a comprehensive range of polyvalent and monovalent diagnostic antisera for bacterial identification.

Mast Group Ltd. exhibited at the Institute of Biomedical Science Congress 2019 at the International Convention Centre in Birmingham 22^nd – 25^th September 2019, and it proved to be a triumph!

Mast Group Ltd has been a manufacturer of antibiotic susceptibility test (AST) products since 1957 and continues to be at the forefront of developments in this field.